Latest Regulatory Approval News

Cuscal Limited reported a 6% revenue increase for FY25 and announced a strategic acquisition of Indue, alongside a leadership change and a higher final dividend.

Vysarn Limited delivered a robust FY2025 performance, driven by significant acquisitions and expanding operations across Australia’s water infrastructure sector. The company’s strategic moves position it well for sustained growth amid evolving market demands.

Reef Casino Trust reported a 23.9% decline in half-year net profit due to higher regulatory and transaction costs, while announcing a recommended takeover bid at $3.72 per unit. The Trust declared a reduced distribution of 6.63 cents per unit.

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.

Papyrus Australia clarifies it has signed a binding term sheet, not a final agreement, with AQN for biodegradable boards, contingent on facility setup and product testing.

Vanadium Resources Limited is progressing towards Direct Shipping Ore operations at Steelpoortdrift, advancing key conditions for a binding offtake agreement with China Precious Asia Limited while optimizing mining readiness and exploring growth opportunities.

Prominence Energy Limited has secured a pivotal natural hydrogen exploration license in South Australia, marking a major step forward for its Gawler Hydrogen Project and positioning it among the state’s leading clean energy explorers.

Reef Casino Trust faces a new takeover challenge as Morris Group submits a conditional $191.7 million cash offer, competing with the board-backed Iris proposal. The trust’s Independent Board Committee urges unitholders to hold off while assessing the competing bids.

Peet Limited reported a robust FY25 with a 60% surge in net profit after tax and declared a higher fully franked dividend, underpinned by strong sales and improved capital management. The company is also undertaking a strategic business review while navigating leadership transitions.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

Downer EDI Limited reported a robust FY25 with a 33% rise in underlying NPATA and announced a $230 million share buy-back, underscoring confidence in its transformation and growth outlook. The company’s disciplined portfolio simplification and operational improvements set the stage for steady FY26 performance despite short-term market softness.

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.